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Abstract
 
The chemokines CXCL9/Mig, CXCL10/IP-10, and CXCL11/I-TAC regulate lymphocyte
chemotaxis, mediate vascular pericyte proliferation, and act as angiostatic agents, thus inhibiting
tumor growth. These multiple activities are apparently mediated by a unique G protein–cou-
pled receptor, termed CXCR3. The chemokine CXCL4/PF4 shares several activities with
CXCL9, CXCL10, and CXCL11, including a powerful angiostatic effect, but its specific re-
ceptor is still unknown. Here, we describe a distinct, previously unrecognized receptor named
CXCR3-B, derived from an alternative splicing of the CXCR3 gene that mediates the angio-
static activity of CXCR3 ligands and also acts as functional receptor for CXCL4.
Human microvascular endothelial cell line-1 (HMEC-1), transfected with either the known
CXCR3 (renamed CXCR3-A) or CXCR3-B, bound CXCL9, CXCL10, and CXCL11,
whereas CXCL4 showed high affinity only for CXCR3-B. Overexpression of CXCR3-A in-
duced an increase of survival, whereas overexpression of CXCR3-B dramatically reduced
DNA synthesis and up-regulated apoptotic HMEC-1 death through activation of distinct signal
transduction pathways. Remarkably, primary cultures of human microvascular endothelial cells,
whose growth is inhibited by CXCL9, CXCL10, CXCL11, and CXCL4, expressed CXCR3-B,
but not CXCR3-A. Finally, monoclonal antibodies raised to selectively recognize CXCR3-B
reacted with endothelial cells from neoplastic tissues, providing evidence that CXCR3-B is also
expressed in vivo and may account for the angiostatic effects of CXC chemokines.
Key words: CXCR3-B • CXCR3-A • angiogenesis • chemokines • chemokines receptor
 
Introduction
 
Chemokines are a family of small, structurally related mol-
ecules that regulate cell trafficking of various subsets of
leukocytes (1–2). Moreover, chemokines regulate embry-
onic development, pathophysiology of the central nervous
system, wound healing repair, control angiogenesis, and
tumor growth and spread (1–4). The nomenclature for
chemokines is based on the configuration of a conserved
amino-proximal cysteine-containing motif. Based on this
system, there are currently four branches of the chemokine
family: CXC, CC, CX
 
3
 
C, and C (where X is any amino
acid). CXC chemokines are characteristically heparin-bind-
ing proteins and exhibit the selective property to promote or
inhibit angiogenesis (4–6). The angiostatic members of the
CXC chemokine family include IP-10/CXCL10, MIG/
CXCL9, I-TAC/CXCL11, and platelet factor 4/CXCL4
(4–6). These chemokines induce injury to established tu-
mor-associated vasculature and promote extensive tumor
necrosis (5–10) and thus have been proposed as useful ther-
apeutic agents in cancer (7).
 
The angiostatic effects of CXCL9, CXCL10, and
CXCL11 on human microvascular endothelial cells
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*
 
 are mediated by the CXC chemokine receptor
3 (CXCR3; 4–6, 11–13), whereas the receptor for CXCL4
has not yet been identified (4, 6). Several studies have
pointed out that CXCL10 and CXCL4 share a great num-
ber of activities, such as inhibition of chemotaxis and prolif-
eration of endothelial cells (14, 15), or inhibition of he-
matopoiesis (16). However, the interaction of CXCL9,
CXCL10, and CXCL11 with CXCR3 also results in the
chemotaxis of activated Th1 cells (17, 18), NK cells (19),
macrophages (20), and dendritic cells (21), whereas CXCL4
does not exert chemotactic activity on the same cell types.
Furthermore, CXCL9 and CXCL10 have been implicated
in the pathogenesis of proliferative glomerulonephritis, a
common renal disease characterized by glomerular hypercel-
lularity, because they induce increased survival and growth
of human mesangial cells (HMC) through their receptor
CXCR3 (22, 23). Recently, we and others found that
CXCL9 and CXCL10 induce chemotaxis and proliferation
(22, 23) of HMC through pertussis toxin–sensitive mecha-
nisms (24). Thus, the apparently opposite effects of CXCL9,
CXCL10, and CXCL11 on HMVEC and on HMC allow
the hypothesis of the existence of cell-specific signal trans-
duction pathways and/or distinct CXCR3 receptor variants.
In this study, we have identified a novel mRNA gener-
ated by an alternative splice site within the intron of the
CXCR3 gene by using rapid amplification of cDNA ends
(RACE) and Northern blot analysis. Real-time quantitative
RT-PCR and transfection of the human microvascular en-
dothelial cell line-1 (HMEC-1) provided evidence for the
existence of a previously unrecognized receptor, named
CXCR3-B, which mediated the inhibitory activity of
CXCL9, CXCL10, and CXCL11 on the growth of HM-
VEC. Binding assay and signal transduction analysis demon-
strated that CXCR3-B also acts as a functional receptor for
CXCL4, thus explaining the large overlap between the bio-
logical activities of CXCL10 and CXCL4. By contrast, the
classic CXCR3 receptor, renamed as CXCR3-A, mediated
the proliferation of HMC in response to CXCL9, CXCL10,
and CXCL11, and was responsible for both increased sur-
vival and angiogenic properties of transfected HMEC-1
cells, but did not react with CXCL4. Finally, mAbs selec-
tively developed against CXCR3-B, reacted with endothe-
lial cells of different human tumor tissues, but poorly or not
with those of their normal counterparts, consistently with
the previously described selective activity of both CXCL4
and CXCL10 on the proliferation of endothelial cells.
 
Materials and Methods
 
Reagents.
 
Recombinant human chemokines were obtained
from R&D Systems (Minneapolis, MN). Pertussin toxin (PTX)
was obtained from Calbiochem.
 
RACE.
 
5
 
  
 
and 3
 
  
 
RACE experiments were performed on
5 
 
 
 
g total RNA obtained from primary cultures of HMVEC or
human thymus using the RLM-RACE kit (GeneRacer; Invitro-
gen), according to the manufacturer’s instructions. Gene-specific
primers used in 5
 
 
 
-RACE were 5
 
 
 
-ACTCTGAGCAGC-
TCCTCCTATAACT-3
 
  
 
and nested 5
 
 
 
-CGCCAGTCTTCCA-
GGGCCGTACTT-3
 
 
 
. Gene-specific primers used in 3
 
  
 
RACE
were 5
 
 
 
-CCTGGAAGACTGGCGGGGACAGTTA-3
 
  
 
and nested
5
 
 
 
-GAGTTCCTGCCAGGCCTTTACAC-3
 
 
 
. The RACE prod-
ucts were cloned into pGEM-T easy vector (Promega) and se-
quenced.
 
Northern Blot Analysis.
 
Human tissue Northern blots pre-
pared with 2 
 
 
 
g poly-A mRNA of each sample (CLONTECH
Laboratories, Inc.) were treated as previously described (25).
 
Real-Time Quantitative RT-PCR (TaqMan™).
 
Total RNA
was extracted (26) and treated with DNase I (QIAGEN) to elim-
inate possible genomic DNA contamination. TaqMan RT-PCR
was performed as previously described (26).
The following primers and probes were used: CXCR3-A:
FAM probe, 5
 
 
 
-TGAGTGACCACCAAGTGCTAAATGA-
CGC-3
 
 
 
; forward 5
 
 
 
-ACCCAGCAGCCAGAGCACC-3
 
 
 
; re-
verse 5
 
 
 
-TCATAGGAAGAGCTGAAGTTCTCCA-3
 
 
 
. CXCR3-B:
VIC probe, 5
 
 
 
-CCCGTTCCCGCCCTCACAGG-3
 
 
 
; forward
5
 
 
 
-TGCCAGGCCTTTACACAGC-3
 
 
 
; reverse 5
 
 
 
-TCGGCG-
TCATTTAGCACTTG-3
 
 
 
. The two sets of primers displayed
similar amplification efficiency and selective specificity, as tested
on a plasmid encoding the CXCR3-A or CXCR3-B cDNA se-
quence, respectively. mRNA levels were quantitated by compar-
ing experimental levels to standard curves generated using serial
dilutions of the same amount of the plasmids. CXCL11,
CXCL10, p21, p53, and GAPDH quantitation was performed
using predeveloped TaqMan assay reagents target kits (Applied
Biosystems). The CXCL9 primers and probes were: FAM
probe, 5
 
 
 
-AAGGGTCGCTGTTCCTGCATCAGC-3
 
 
 
; forward
5
 
 
 
-TGCAAGGAACCCCAGTAGTGA-3
 
 
 
; reverse 5
 
 
 
-GGTG-
GATAGTCCCTTGGTTGG-3
 
 
 
. GAPDH was used for nor-
malization.
 
Generation of HMEC-1 and HEK-293EBNA Stable Transfectants
for CXCR3-A and CXCR3-B.
 
Full-length CXCR3-A and
CXCR3-B cDNAs were obtained by RT-PCR performed on
total mRNA derived from human thymus and HMVEC, re-
spectively, cloned in expression vectors carrying the same pro-
moter and polyadenylation signal, pCEP4 (27) and pTarget
(Promega), respectively, sequenced, and transfected into
HMEC-1 (28) and HEK-293EBNA (Invitrogen) by electropo-
ration. Stably transfected cells were selected using MCDB 131
or DMEM media containing 300 
 
 
 
g/ml hygromycin or 500
 
 
 
g/ml G-418, respectively. CXCR3-A and CXCR3-B expres-
sion was revealed by FACS
 
® 
 
analysis with CXCR3-specific 1C6
(BD Biosciences) and 49801.111 (R&D Systems) mAbs, as pre-
viously described (11).
 
Binding Assays.
 
Iodination of human recombinant CXCL4
was performed using the chloramine-T method (29). The spe-
cific activity of the 
 
125
 
I-CXCL4 was 360.2 
 
 
 
Ci/
 
 
 
g. Binding as-
says were performed as previously described (30). In brief, cells
were plated in 24-well culture plates and incubated overnight in
standard medium. For the binding assay, cells were washed twice
with washing buffer (0.5 M NaCl, 50 mM Hepes, 1mM CaCl
 
2
 
,
5mM MgCl
 
2
 
, and 1% BSA, pH 7.2), once with binding buffer
(washing buffer without NaCl), and then incubated in duplicate
with a constant concentration (18 pM) of 
 
125
 
I-labeled CXCL10
(Amersham Biosciences) or 
 
125
 
I-labeled CXCL4 in the presence
of increasing concentrations of unlabeled chemokines. Incuba-
 
*
 
Abbreviations used in this paper:
 
 CXCR3, CXC chemokine receptor 3;
GPCR, G protein–coupled receptor; HMC, human mesangial cells;
HMEC-1, human microvascular endothelial cell line-1; HMVEC, hu-
man microvascular endothelial cells; PTX, pertussin toxin; RACE, rapid
amplification of cDNA ends; TUNEL, terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick end labeling.T
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tions took place in 200 
 
 
 
l binding buffer. After incubation at
room temperature for 2 h, binding buffer was aspirated and cells
were washed once in PBS (without Ca and Mg) and then lysed
in 0.5 ml 1 N NaOH. Radioactivity was determined using a
gamma counter. Data were analyzed using the computer pro-
gram ALLFIT (31). These salt conditions have been optimized
for chemokine binding and minimize the potential for chemo-
kine self-association (32).
 
Flow Cytometric Analysis of Calcium Mobilization.
 
10
 
6 
 
cells
were loaded with 5 mM Indo-1 acetyloxy methyl ester for 45
min at 37
 
 
 
C, washed, and then incubated for an additional 45
min at 37
 
 
 
C. Variation in the intracellular calcium concentration
[Ca
 
  
 
]i was measured by evaluating the 525/405-nm emission
ratio of unstimulated (baseline), chemokine-, or ionomycin- (cell
loading control) stimulated Indo-1–loaded cells.
 
Cell Cultures.
 
HMEC-1, HMC, and ACHN cells were cul-
tured as previously described (28, 25, 33).
 
cAMP Detection Immunoassay.
 
cAMP levels were assessed by
using a commercially available colorimetric kit (Calbiochem) on
40,000 cells/well.
 
Cell Proliferation Assay.
 
[
 
3
 
H]thymidine incorporation was as-
sessed as previously described (11). To perform blocking experi-
ments, a neutralizing anti–human CXCL11/I-TAC mAb (clone
87328) was obtained from R&D Systems.
 
Terminal Deoxynucleotidyl Transferase-mediated dUTP Nick End
Labeling (TUNEL) Assay.
 
HMEC-1 transfectants were stained
using the TUNEL method (Apoptag
 
®
 
 kit, Oncor
 
®
 
; reference 34),
and the number of labeled nuclei was assessed by cell counting.
 
Flow Cytometric Apoptosis Assays.
 
HMEC-1 transfectants were
processed for FACS
 
® 
 
analysis as previously described (11). The
percentage of cells with a sub-G1 DNA content was taken as a
measure of apoptosis cell rate.
 
Matrigel Morphogenetic Assay.
 
HMEC-1 transfectants (2 
 
 
 
10
 
4
 
/well) were plated onto 0.2 ml Matrigel (Becton Dickinson)
and observed after a 48-h culture.
 
Chemotactic Assay.
 
Chemotaxis on HMEC-1 transfectants
(5 
 
  
 
10
 
4
 
/well) was performed as previously described (24).
 
mAb Production.
 
CXCR3-B–specific mAbs were generated at
Primm by immunizing BALB/c mice with 100 
 
 
 
g of a 51-mer
synthetic peptide corresponding to the first 51 NH
 
2
 
-terminal
amino acids of CXCR3-B (MELRKYGPGRLAGTVIGG-
AAQSKSQTKSDSITKEFLPGLYTAPSSPFPPSQ). This peptide
was synthesized and coupled to ovalbumin. mAbs reactive with
the peptide used for immunization were screened by ELISA of
ibridomas supernatants. CXCR3-B specificity of the obtained
mAbs was checked using untransfected and CXCR3-A– or
CXCR3-B–transfected HMEC-1 cells and immunostaining. The
two main mAbs used in this study (PL1 and PL2) had an IgG1
isotype.
 
Immunofluorescence and Immunohistochemistry.
 
Immunohisto-
chemistry was performed as previously described (11). Anti–
CXCR3-B mAbs purified ascites fluid of clones PL1 and PL2
were used at a final dilution of 3 
 
 
 
g/ml and 20 
 
 
 
g/ml, respec-
tively, and the Vectastain ABC kit (Vector Laboratories) was
used as a detection system. Pre-adsorption test was performed by
preincubating the mAbs overnight at 4
 
 
 
C with the specific pep-
tide used to immunize mice (2 mg). CXCR3-B and von Wille-
brand factor (anti-vWf Ab, 1:8,000; DakoCytomation) were
colocalized on the same sections by double label immunohis-
tochemistry (11).
 
Tumor Tissues.
 
Tumor specimens were obtained from 10
subjects suffering from nonsmall cell lung cancer and from 7 sub-
jects suffering from renal cell carcinoma and their normal coun-
 
terparts, who underwent surgical excision, in accordance with
the Regional Ethical Committee on human experimentation.
 
Results
 
Identification, Molecular Characterization, and Tissue Distri-
bution of a Novel CXCR3 Variant (CXCR3-B).
 
Transla-
tion of the CXCR3 gene with an automated computer
program (ExPASy, available at http://ca.expasy.org) to
search for novel sequence variants, identified the possible
existence of a second mRNA. The predicted 1,248-bp
open reading frame of this mRNA was initiated from an al-
ternate in-frame ATG start codon found within the intron
sequence and 151-bp upstream of the known AG acceptor
site used for intron splicing (Fig. 1 a). Translation of
CXCR3-B mRNA generated a 416–amino acid receptor
containing a longer NH
 
2
 
-terminal extracellular domain dif-
ferent from the CXCR3-A sequence in the first 52 amino
acid residues, whereas the remaining protein was identical
(Fig. 1 a). To provide evidence for the existence of, and to
better characterize, this new mRNA, a rapid amplification
of complementary cDNA 5
 
  
 
and 3
 
  
 
ends (RACE) on total
mRNA obtained from either primary cultures of HMVEC
or human thymus was performed by using primers selec-
tively hybridizing the final portion of the intron (Fig. 1, a
and b). This new mRNA, named CXCR3-B, showed
a large overlap with the known CXCR3 sequence, but a
novel 5
 
  
 
end resulting from an alternative splicing between
the same donor site used by the known CXCR3 sequence
(renamed CXCR3-A) and a novel acceptor site localized
233 bp upstream of the known AG acceptor site (Fig. 1, a–c).
The size of CXCR3-B, including the 5
 
  
 
UTR region,
was 1,860 bp (sequence data are available from GenBank/
EMBL/DDBJ under accession no. AF469635). Further-
more, screening of the ResGene Clone Collection database
identified a clone (ID 19600412004045), obtained from a
cDNA leukocyte library (NFLHAL1), showing complete
homology with the first 567 bp of the CXCR3-B se-
quence, the last 269 bp of this clone overlapping the se-
quence common to both receptors. The expression of this
new putative mRNA was assessed in different tissues by us-
ing Northern blot analysis. To this end, a 182-bp probe
(Fig. 1 a, yellow) selectively hybridizing with the CXCR3-B
mRNA was used, which recognized an mRNA of 
 
 
 
1.8
kb, mainly expressed in the heart, kidney, liver, and skeletal
muscle (Fig. 1 d, top). By using a 401-bp cDNA probe
(Fig. 1 a, light green) encompassing a region shared by both
receptors, two distinct mRNAs of 
 
 
 
1.8 (CXCR3-B) and
1.6 kb (CXCR3-A) were detected in the heart, kidney,
liver, and skeletal muscle, with CXCR3-A being consis-
tently prevalent (Fig. 1 d, bottom). Only CXCR3-A
mRNA was observed in the placenta (Fig. 1 d, bottom).
 
CXCR3-B Binds CXCL10, CXCL11, CXCL9, and
CXCL4.
 
To better investigate whether CXCR3-B and
CXCR3-A had different properties, stable CXCR3-A or
CXCR3-B transfectants were generated by using the
HMEC-1 cell line. CXCR3-A transfectants exhibited
high surface receptor expression (Fig. 2 a), whereas surfaceT
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
1540
 
Cell Growth Inhibition via a Novel Type of Chemokine Receptor
 
receptor expression in CXCR3-B transfectants was usually
consistently lower (Fig. 2 b). One clone of CXCR3-A–
and one of CXCR3-B–transfected cells, which exhibited
comparable levels of surface receptor, were assessed for
their ability to bind CXCL9, CXCL10, and CXCL11. All
CXCR3 ligands displaced binding of 
 
125
 
I-CXCL10 from
CXCR3-A with a higher affinity than from CXCR3-B.
CXCL10 displaced 
 
125
 
I-CXCL10 bound to CXCR3-A
transfectants with an IC50 of 0.35 
 
  
 
0.1 nM, CXCL11
with an IC50 of 0.41 
 
  
 
0.14 nM, and CXCL9 with an
IC50 of 33 
 
  
 
24 nM (Fig. 2 c). The highest affinity bind-
ing for CXCR3-B was displayed by CXCL10 (IC50 
 
 
 
6.9 
 
  
 
2.1 nM), whereas CXCL11 displaced radiolabeled
CXCL10 bound to CXCR3-B transfectants with an IC50
of 32   10.2 nM and CXCL9 with an IC50 of 133   46.5
nM (Fig. 2 d). The binding of 125I-CXCL10 to either
CXCR3-A or CXCR3-B transfectants was completely in-
hibited by the 49801.111 mAb used at concentrations of
10 or 1  g/ml, respectively, demonstrating that this mAb
was able to neutralize the functional activity of both
CXCR3 receptor variants (unpublished data). HMEC-1
cells transfected with the empty vector (mock) did not
bind 125I-CXCL10.
Because CXCR3-B apparently acted as a novel chemo-
kine receptor, the binding to CXCR3-B transfec-
tants of many chemokines was assessed. CCL1/I-309,
CCL2/MCP-1, CCL3/MIP-1 , CCL4/MIP-1 , CCL5/
RANTES, CCL11/eotaxin, CCL17/TARC, CCL19/
ELC, CCL21/SLC, CCL22/MDC, CCL25/TECK,
CXCL1/GRO- , CXCL2/GRO- , CXCL3/GRO- ,
CXCL5/ENA-78, CXCL8/IL-8, and CXCL12/SDF-1
did not compete for radiolabeled CXCL10 binding on
CXCR3-B transfectants (unpublished data). However,
CXCL4, which shares with CXCL10, CXCL9, and
CXCL11 several activities including a powerful angiostatic
effect, displaced the binding of 125I-CXCL10 to CXCR3-B
transfectants under the same conditions with an IC50 of
7.46   3.05 nM (Fig. 2 f). By contrast, very poor displace-
ment of 125I-CXCL10 binding to CXCR3-A transfectants
(IC50   448   152 nM; Fig. 2 e) was observed. To pro-
vide direct evidence that CXCL4 binds to CXCR3-B and
to measure its affinity, binding assays with 125I-CXCL4
were performed. Radiolabeled CXCL4 bound specifically
to CXCR3-B transfectants (Fig. 2 h), but neither to mock
(unpublished data) nor to CXCR3-A transfectants (Fig. 2
g). More importantly, the binding of radiolabeled CXCL4
Figure 1. Identification, molecular characterization, and tissue distribution of CXCR3-B. (a) Structure of the human CXCR3 gene. Upper case, the
exons; lower case, the intron; arrow, the CXCR3-B transcription start; underline, the CXCR3-B translation start site (ATG); light shading, the donor
(AG/gt, common for both CXCR3-A and CXCR3-B) and acceptor (ag/GG, CXCR3-B; AG/GT, CXCR3-A) splice sites. The nested primers used
for 5  and 3  RACE are boxed and the direction is pointed by the arrow. The 182-bp probe (recognizing CXCR3-B) and the 401-bp probe (recogniz-
ing both CXCR3-A and CXCR3-B) used for Northern blot analysis are evidenced in yellow and light green, respectively. (b) RACE performed on pri-
mary cultures of HMVEC. Lane 1, DNA ladder Marker VIII; lane 2, 5  RACE product; lane 3, 3  RACE product; lane 4, DNA ladder 1 Kb plus. (c)
Schematic representation illustrating the generation of CXCR3-A and CXCR3-B mRNA through alternative splicing. (d) Multiple tissue Northern blot
hybridization with the 182-bp probe (top) or the 401-bp probe (bottom). These sequence data are available from GenBank/EMBL/DDBJ under
accession no. AF469635.T
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to CXCR3-B transfectants was displaceable by increasing
concentrations of unlabeled CXCL4, with an IC50 of
1.85   0.9 nM (Fig. 2 h). The binding of 125I-CXCL4 to
CXCR3-B transfectants was completely inhibited by the
addition of anti-CXCR3 mAb 49801.111 used at the con-
centration of 20  g/ml (unpublished data). Because
CXCL4 exhibited high affinity and selectivity for
CXCR3-B, whereas CXCL10, CXCL11, and CXCL9
bound CXCR3-A with higher affinity, we suggest that
CXCL4 is the dominant ligand for CXCR3-B.
Selective Overexpression of CXCR3-A or CXCR3-B Has
Opposite Effects on Both Growth and Angiogenic Activity of En-
dothelial Cells. To further investigate the functions of
CXCR3-B, 29 clones of CXCR3-B, and 26 clones of
CXCR3-A, transfectants were screened for cell viability,
proliferation, apoptosis, and ability to induce vessel forma-
tion in vitro. All clones expressing high CXCR3-B levels
on their surface rapidly died within two or three passages.
Only six clones expressing low CXCR3-B levels survived
for 8–10 passages. However, all exhibited a lower prolifera-
tion rate than the respective mock transfectants, as demon-
strated by either assessing [3H]thymidine incorporation on
day 3 (2,623   234 vs. 10,748   1,820 cpm/well; P  
0.001) or counting the numbers of viable cells in 60-mm
wells on day 7 (370,000    20,000 vs. 1,570,000  
250,000; P    0.001). Low proliferation of CXCR3-B
clones was related to a high degree of apoptotic cell death
as shown by either FACS® analysis of sub-G1 DNA con-
tent (Fig. 3 a) or detection of DNA fragmentation with
TUNEL immunostaining (Fig. 3 a, inset). Furthermore,
these clones were unable to induce tube-like vessel forma-
tion in the Matrigel assay in vitro (Fig. 3 b) and did not
reach confluence in culture, suggesting the presence of
contact inhibition. Of note, however, CXCR3-B transfec-
tion of HEK293-EBNA cells resulted in little, if any, in-
hibitory effect on their proliferation (unpublished data),
suggesting that CXCR3-B expression does not have the
same effects on any cell type. By contrast, all 26 clones ex-
hibiting high levels of CXCR3-A displayed higher
[3H]thymidine incorporation on day 3 (36,323   8,234 vs.
9,932   2,287 cpm/well; P   0.001), higher numbers of
viable cells in 60-mm wells on day 7 (2,450,000   150,000
vs. 1,250,000   250,000; P   0.001), lower degree of apop-
totic cell death (Fig. 3 c), and higher capability to induce
tube-like vessel formation in the Matrigel assay (Fig. 3 d)
than the respective mock transfectants. Moreover, although
CXCR3-A transfectants showed chemotactic response to
CXCL10, CXCL9, CXCL11, CXCL8, CXCL12, or basic
fibroblast growth factor, CXCR3-B transfectants did not
exhibit chemotactic response to any of these factors (un-
published data), suggesting inhibition by CXCR3-B ex-
pression even on endothelial cell chemotaxis.
The differences in cell growth, viability, and angiogenic
capability between CXCR3-A or CXCR3–B transfec-
tants, allowed us to hypothesize the constitutive production
by these cells of one or more CXCR3 ligand. By using
real-time quantitative RT-PCR and FACS® analysis, high
mRNA and protein levels for CXCL11 were indeed ob-
served in all transfectants, including mock (Fig. 3, e and f).
Accordingly, the addition in culture of an anti-CXCL11
mAb reduced the spontaneous proliferation of CXCR3-A
transfectants, but enhanced the proliferation of CXCR3-
B–transfected cells (Fig. 3 g). However, despite the high
constitutive expression of CXCL11 on their surface, both
CXCR3-A and CXCR3-B transfectants still responded to
CXCL10 with increased or decreased proliferation, respec-
tively (Fig. 3 h). Notably, in agreement with the higher af-
finity of CXCR3-A than CXCR3-B for CXCL10, the in-
Figure 2. CXCR3-A and CXCR3-B expression by HMEC-1 trans-
fectants and their binding affinity to cognate ligands. (a) Flow cytometric
analysis of surface CXCR3-A. (b) Flow cytometric analysis of surface
CXCR3-B. (c) CXCL10, CXCL9, and CXCL11 displacement of 125I-
labeled CXCL10 bound to CXCR3-A transfectants. (d) CXCL10,
CXCL9, and CXCL11 displacement of 125I-labeled CXCL10 bound
to CXCR3-B transfectants. (e) Lack of significant displacement by cold
CXCL4 of 125I-labeled CXCL10 bound to CXCR3-A transfectants. (f)
CXCL4 displacement of 125I-labeled CXCL10 bound to CXCR3-B
transfectants. (g) Lack of significant binding of CXCL4 to CXCR3-A
transfectants. (h) High affinity binding of CXCL4 to CXCR3-B transfec-
tants. Figures show mean displacement curves generated by analysis with
the Allfit software obtained in eight separate experiments.T
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hibition of proliferation on CXCR3-B transfectants could
be observed at 2.5–5  M, whereas proliferative effects on
CXCR3-A transfected cells peaked at 500-nM concentra-
tions (Fig. 3 h). Inhibitory effects on the proliferation of
CXCR3-B transfectants quite similar to those induced by
CXCL10 were also induced by CXCL4, whereas even at
higher concentrations the latter chemokine exerted poor, if
any, stimulatory effects on the proliferation of CXCR3-A
transfectants (Fig. 3 i).
CXCR3-A and CXCR3-B Activate Distinct Signal Trans-
duction Pathways. Chemotactic activity of chemokine re-
ceptors is due to their coupling to heterotrimeric G protein
Gi, which mediates intracellular Ca   flux and can be in-
activated by pretreatment with PTX. However, differently
from CXCR3-A, CXCR3-B was apparently unable to
mediate chemotactic activity. To investigate whether
CXCR3-B was also coupled to Gi protein, CXCR3-A
and CXCR3-B transfectants were incubated for 24–72 h
with 1  g/ml PTX and thymidine incorporation was as-
sessed. As expected, PTX strongly reduced proliferation of
CXCR3-A transfectants in basal conditions as well as after
treatment with 500 nM CXCL10 (Fig. 4 a), whereas it did
not affect the proliferation of CXCR3-B transfectants ei-
ther in basal conditions nor after treatment with 4  M
CXCL10 (Fig. 4 b). Effects were also not observed in
mock nor in untransfected cells (unpublished data). The
signal transduction pathways activated by CXCR3-A or
CXCR3-B were then investigated. CXCR3-A transfec-
tants exhibited a rapid, dose-dependent [Ca  ]i flux in re-
sponse to CXCL9, CXCL10, and CXCL11, but poor if
any to CXCL4 (Fig. 4 c). By contrast, CXCR3-B trans-
fectants did not mediate calcium flux in response to the
four chemokines over a dose ranging from 10 pM to 1  M
(unpublished data).
To identify the alternative pathway involved in
CXCR3-B–mediated signal transduction, cAMP produc-
tion in CXCR3-B transfectants was assessed. Basal cAMP
levels were highly increased in comparison with mock
Figure 3. Functional properties of
CXCR3-A- and CXCR3-B-transfected
cells. (a) Apoptosis in CXCR3-B transfec-
tants as assessed by detection with flow cy-
tometry of the percentage of cells with a
sub-G1 DNA content or of cells showing
DNA fragmentation by using the TUNEL
technique (inset). Results are from one rep-
resentative of four experiments. (b) In vitro
vessel formation capability of CXCR3-B
transfectants as assessed by the Matrigel as-
say. Data are from one representative of
four independent experiments. (c) Apopto-
sis in CXCR3-A–transfected cells (for de-
tails see Fig. 4 a). (d) In vitro vessel forma-
tion capability of CXCR3-A transfectants
(for details see Fig. 4 b). (e) Detection of
CXCL11 mRNA expression by HMEC-1
as assessed by real-time quantitative RT-PCR.
Columns represent mean values ( SD) of
four separate experiments. (f) Flow cyto-
metric analysis on HMEC-1 of CXCL9,
CXCL10, and CXCL11 protein. Black line,
isotype control mAb; green line, CXCL10;
light blue, CXCL9; pink line, CXCL11.
Data are from one representative of five in-
dependent experiments. (g) Opposite effects
of neutralizing anti-CXCL11 mAb on the
proliferation of CXCR3-A (open bar) and
CXCR3-B (solid bar) transfectants. Results
represent mean values ( SD) of the per-
centage of proliferation over isotype con-
trols obtained in four separate experiments.
(h) Opposite effects of CXCL10 on the
proliferation of CXCR3-A (left bars) and
CXCR3-B (right bars) transfectants. (i) Ef-
fects of CXCL4 on the proliferation of
CXCR3-A (left bars) and CXCR3-B (right
bars) transfectants. Results represent mean
values ( SD) of the percentage of prolifer-
ation over controls (unstimulated cells)
from four separate experiments *, P   0.05;
**, P   0.001.T
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(1.9   0.47 vs. 0.69   0.09 pmol/ml; P   0.05), suggest-
ing chronic activation of adenylyl cyclase activity due to a
receptor-mediated mechanism in CXCR3-B transfectants.
However, despite their high constitutive cAMP levels, the
addition of 1–5  M CXCL10, CXCL9, CXCL11, or
CXCL4 significantly increased intracellular cAMP levels in
CXCR3-B transfectants and also potentiated forskolin-
induced cAMP levels (Fig. 4 d) with a peak response at 2 h.
The increase of cAMP levels induced by CXCL10,
CXCL9, CXCL11, or CXCL4 in CXCR3-B transfectants
was PTX insensitive (unpublished data). Of note, the same
chemokines did not induce any significant increase of
cAMP levels in either mock cells nor CXCR3-A transfec-
tants (unpublished data).
The effects of CXCL10 and CXCL4 on the expression
of cell cycle regulatory molecules, such as p21CIP1/
WAF1 and p53, was then investigated. Basal levels of p53
mRNA were comparable in CXCR3-A and CXCR3-B
transfectants, whereas p21 mRNA levels were at least 10
times higher in CXCR3-B compared with CXCR3-A
transfectants (Fig. 4, e and f). CXCL4 had virtually no ef-
fect on both p21 and p53 mRNA expression by
CXCR3-A–transfected cells. By contrast, CXCL4 sig-
nificantly up-regulated p21 mRNA transcription in
CXCR3-B transfectants (Fig. 4 c), but had no effect on
the transcription of p53 mRNA (Fig. 4 f). Quite similar
effects were induced by the same concentrations of
CXCL10 (unpublished data).
Figure 4. Activation of dis-
tinct signal transduction
pathways in CXCR3-A and
CXCR3-B transfectants. (a) In-
creased proliferative activity
in CXCR3-A transfectants is
strongly reduced by PTX both
in basal conditions and after treat-
ment with 500 nM CXCL10.
(b) PTX has no effect on the
proliferation of CXCR3-B trans-
fectants both in basal conditions
and after treatment with 4  M
CXCL10. Cells were incubated
for 60 h with 1  g/ml PTX and
thymidine incorporation was
assessed in the last 12 h. Col-
umns represent mean values
( SD) of three separate experi-
ments. *, P   0.05. (c) Induction
by CXCL10, CXCL9, and
CXCL11 (1  M), but not by
CXCL4 (1  M), of Ca   mobi-
lization in CXCR3-A transfec-
tants. Results are from one rep-
resentative of four experiments.
(d) Effect of CXCL10, CXCL9,
CXCL11, and CXCL4 (2  M)
on basal cAMP production and
of CXCL10 and CXCL4 (2  M)
on forskolin (1  M)-stimulated
cAMP production in CXCR3-B
transfectants. Columns represent
mean values ( SD) of six sepa-
rate experiments. *, P   0.05; **,
P     0.001. (e) Absence of
p21Cip1/Waf1 and p53 regula-
tion by CXCL4 in CXCR3-A
transfectants as assessed by real-
time quantitative RT-PCR. (f)
Up-regulation in CXCR3-B
transfectants of p21Cip1/Waf1,
but not of p53, mRNA levels by
increasing concentrations of
CXCL4 as assessed by real-time
quantitative RT-PCR. T
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Cell Type–specific Transcription of CXCR3-A and CXCR3-B
and Their Related Functions. The expression of CXCR3-A
and CXCR3-B mRNA in different cell types, known to
express CXCR3, was then investigated. Assessment of
CXCR3-A and CXCR3-B mRNA by real-time quantita-
tive RT-PCR revealed the presence of both CXCR3-A
and CXCR3-B mRNAs in activated peripheral blood T
lymphocytes, CXCR3-A expression being consistently
prevalent (Fig. 5 a). By contrast, primary cultures of
HMC expressed CXCR3-A, but not CXCR3-B, mRNA,
whereas CXCR3-B was the only type of CXCR3 present
in primary cultures of HMVEC (Fig. 5 a). In agreement
with previous reports (22), CXCL10 strikingly up-regu-
lated HMC proliferation with a peak response at 36 h to a
concentration of 1 nM (Fig. 5 b), an effect which was com-
pletely inhibited by the anti-CXCR3 mAb 49801.111
(Fig. 5 b). By contrast, CXCL10 induced growth inhibi-
tion of both HMVEC (Fig. 5 c) with a peak response oc-
curring at 72 h at a concentration of 100 nM–1  M. This
inhibitory effect was reversed by the addition of the anti-
CXCR3 mAb 49801.111 (Fig. 5, c and d). CXCL4 in-
duced comparable inhibitory effects on the growth of HM-
VEC (Fig. 5, c and d), which were also inhibited by the
anti-CXCR3 mAb 49801.111 (Fig. 5 c), whereas CXCL9
and CXCL11 usually had lower inhibitory effects (unpub-
lished data).
To provide evidence that CXCR3-B was expressed and
functional on other cell types, mRNA levels for CXCR3-A
and CXCR3-B were assessed by quantitative RT-PCR
on different human cell lines. Among the cell types ana-
lyzed, the highest levels of CXCR3-B were observed in
the renal carcinoma ACHN cell line, where CXCR3-A
mRNA was not detectable (Fig. 5 d). Interestingly, the re-
nal carcinoma ACHN cell line is well known for its prop-
erty to undergo growth inhibition in response to IFNs
(33). FACS® analysis using the 49801.111 mAb demon-
strated surface expression of CXCR3 on  30% of the
cells (Fig. 5 e). The binding assay performed on the
ACHN cell line using CXCL9, CXCL10, CXCL11, and
CXCL4 demonstrated a single class of high affinity bind-
ing sites for CXCL10 (IC50   2.30   1.44 nM; Fig. 5 f),
CXCL4 (IC50   6.83   4.37 nM; Fig. 5 f), CXCL9
(IC50     88.45     69.3 nM; unpublished data), and
CXCL11 (IC50   49.58   11.27 nM; unpublished data),
characterized by an IC50 comparable to the one showed
by the same ligands for CXCR3-B. CXCL10 and
CXCL4 induced growth inhibition of the ACHN cell line
with a peak response occurring at 72 h at micromolar
Figure 5. Cellular expression of
CXCR3-A (solid bars) and CXCR3-B
(hatched bars) and their opposite effects on
the proliferation of different cell types. (a)
CXCR3-A and CXCR3-B expression by
peripheral blood–activated T cells, HMC,
and HMVEC as assessed by real-time quan-
titative RT-PCR. Columns represent mean
values ( SD) of eight separate experiments.
(b) Up-regulation of HMC growth by
CXCL10 and its inhibition by an anti-
CXCR3 mAb. (c) Inhibitory effect of
CXCL4 and of CXCL10 on the prolifera-
tion of HMVEC. The inhibitory effects of
both CXCL4 and CXCL10 are reverted by
an anti-CXCR3 mAb. (d) Selective expres-
sion of CXCR3-B mRNA by the ACHN
cell line as detected by quantitative RT-
PCR. (e) Surface expression of CXCR3 on
the membrane of ACHN cells as detected
by FACS®  analysis performed with the
49801.111 mAb. (f) Demonstration of a sin-
gle type of surface receptor in ACHN cells
with an IC50 for CXCL10 and CXCL4
comparable to that observed for CXCR3-B.
(g) Inhibitory effect of CXCL4 and of
CXCL10 on the proliferation of ACHN
cells. The inhibitory effects of both CXCL4
and CXCL10 are reverted by an anti-
CXCR3 mAb. (h) Effect of CXCL10 (2
 M) on basal cAMP production and of
CXCL10 (2  M) on forskolin (1  M)-
stimulated cAMP production in CXCR3-B
transfectants. Columns represent mean val-
ues ( SD) of six separate experiments. *, P   0.05; **, P   0.001. (i) Up-regulation in CXCR3-B transfectants of p21Cip1/Waf1, but not of p53,
mRNA levels by increasing concentrations of CXCL4 as assessed by real-time quantitative RT-PCR. Symbols represent mean values ( SD) of four
separate experiments. *, P   0.01.  , CXCL4 plus 20  g/ml isotype mAb;  , CXCL4 plus 20  g/ml anti-CXCR3 mAb;  , CXCL10 plus 15  g/ml
isotype mAb;  , CXCL10 plus 15  g/ml anti-CXCR3 mAb (clone 49801.111).T
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concentrations (Fig. 5 g). The inhibitory effect of both
CXCL10 and CXCL4 was reversed by the addition of
anti-CXCR3 mAb 49801.111 (Fig. 5 g). Additional evi-
dence that ACHN cells selectively expressed functional
CXCR3-B was provided by the demonstration that they
responded to 2  M CXCL10, CXCL9, CXCL11, or
CXCL4 with a significant increase of intracellular cAMP
levels as well as potentiation of forskolin-induced cAMP
levels (Fig. 5 h). Finally, treatment of the ACHN cell line
with CXCL10 and CXCL4 induced a significant p53-
independent up-regulation of p21 mRNA transcription
(Fig. 5 i).
CXCR3-B Protein Expression by Endothelial Cells of Hu-
man Neoplastic Tissues. To investigate the expression of
CXCR3-B in vivo, mAbs able to selectively recognize
CXCR3-B apart from CXCR3-A were raised against a
peptide corresponding to the NH2-terminal region of the
CXCR3-B receptor. When tested by immunohistochem-
istry, two mAbs (PL1 and PL2) stained CXCR3-B, but
not mock nor CXCR3-A, transfectants (Fig. 6, a–c). Fur-
thermore, primary cultures of HMC did not react with the
same anti–CXCR3-B mAbs (Fig. 6 d), whereas primary
cultures of HMVEC (Fig. 6 e), as well as the ACHN cell
line (Fig. 6 f), were positively stained. The anti–CXCR3-B
Figure 6. Detection of CXCR3-B
protein expression by different types
of cell cultures and by endothelial
cells of human neoplastic tissues by
CXCR3-B–specific mAbs. (a) Ab-
sence of reactivity in mock transfec-
tants stained with an anti-CXCR3-B
mAb.  100. (b) Intense staining of
CXCR3-B transfectants with an
anti–CXCR3-B mAb.  100. (c)
Absence of reactivity in CXCR3-A
transfectants stained with an anti–
CXCR3-B mAb.  100. (d) Ab-
sence of reactivity in primary
cultures of HMC stained with an
anti–CXCR3-B mAb.  100. (e)
Positive staining of primary cultures
of HMVEC as well as the ACHN
cell line (f) with an anti–CXCR3-B
mAb.  100. (g) Absence of reactiv-
ity in normal human renal tissue
stained with PL1 anti–CXCR3-B
mAb.   10. (h) Staining with the
same mAb of endothelial cells in a
specimen of renal cell carcinoma. (i)
Staining of both endothelial and tu-
mor cells with the anti-CXCR3
mAb 49801.111 tested in an adjacent
section. (j) Absence of reactivity in
an adjacent section stained with an
isotype-matched control mAb. (k
and l) Reactivity of endothelial cells
from the same renal carcinoma spec-
imen before and after adsorption of
PL1 mAb with the peptide used for
mouse immunization. (m) Reactivity
with PL1 mAb of endothelial cells
from a group of vessels in a renal cell
carcinoma specimen as detected at a
higher power magnification.  250.
(n) Staining of an adjacent section
with PL2 anti–CXCR3-B mAb. (o)
Double label immunohistochemis-
try for CXCR3-B (red) and vWf
(blue-gray), showing costaining
(brown). (p) Absence of CXCR3-B
reactivity in normal human lung tissue
stained with PL1 anti–CXCR3-B
mAb. (q) Staining with the same
mAb of endothelial cells in a speci-
men of NSCLC. (r) Staining of both
endothelial cells and other cell
types  with the anti-CXCR3 mAb
49801.111 in an adjacent section.T
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1546 Cell Growth Inhibition via a Novel Type of Chemokine Receptor
mAbs also stained vessels from neoplastic tissues (Fig. 6 h,
k, m–o, and r), but poorly or not from their normal coun-
terparts (Fig. 6, g and p). Preadsorption with the peptide
used to generate mAbs completely abolished the staining
(Fig. 6 l). Moreover, comparison of immunostaining on
the same tumor specimens between the anti–CXCR3-B
mAb and the anti-CXCR3 mAb 49801.111, which reacts
with a portion of the receptor shared by both CXCR3-B
and CXCR3-A (Fig. 6, h vs. i and q vs. r), as well as dou-
ble label immunohistochemistry with anti–CXCR3-B plus
vWf (Fig. 6 o), demonstrated that staining of neoplastic tis-
sues was due to CXCR3-B expression by their endothelial
cells.
Discussion
The chemokines CXCL9, CXCL10, and CXCL11 ex-
hibit several activities, including the induction of prolifera-
tion of HMC (22, 23) and the inhibition of endothelial cell
growth (4–10). The results of this study provide evidence
that these opposite functions can be explained by the inter-
action of these chemokines with two distinct receptors. In
addition to the classic form of CXCR3 receptor, here re-
named CXCR3-A, a novel CXCR3 receptor variant,
named CXCR3-B, derived from an alternative splicing be-
tween the same donor site used for CXCR3-A and a novel
acceptor site localized within the intron of the CXCR3
gene, was identified. Transfection of the two receptors in
an HMEC-1 resulted in differences in cell morphology, vi-
ability, proliferative activity, apoptosis, and angiogenic ca-
pability. CXCR3-A overexpression enhanced cell viability
and proliferation, induced rescue from apoptotic cell death,
and increased ability of vessel formation in vitro. By con-
trast, overexpression of CXCR3-B resulted in altered
growth properties and massive apoptotic cell death. These
opposite effects were related to constitutive expression of
CXCL11 on the surface of all transfectants, as demonstrated
by the fact that the addition of an anti-CXCL11 mAb re-
duced the spontaneous proliferation of CXCR3-A–trans-
fected cells and enhanced the proliferation of CXCR3-B–
transfected cells. However, despite the high constitutive
expression of CXCL11 on their surface, CXCR3-A– and
CXCR3-B–transfected cells still responded to high concen-
trations of CXCL10 with further increase or decrease of
their proliferation, respectively. These findings provide a
convincing explanation for both the proliferation induced
by CXCL9, CXCL10, and CXCL11 on HMC, which se-
lectively express CXCR3-A (22, 23), and the inhibitory ac-
tivity exerted by the same chemokines on the proliferation
of HMVEC (11, 12, 14, 16), which selectively express
CXCR3-B. CXCR3-A showed higher affinity than
CXCR3-B for all three chemokines, thus explaining why,
in the case of coexpression of the two receptors on the same
cell type, CXCR3-A–mediated effects become prevalent.
These data, together with the demonstration that presently
available anti-CXCR3 Abs react with both receptors (un-
published data), account for why the existence of the sec-
ond receptor had not previously been recognized.
An additional and unexpected finding emerging from
this study is the demonstration that CXCR3-B acts as a
functional receptor for CXCL4. CXCL4 is also a member
of CXC chemokines released in high concentrations from
activated platelets (35), which is involved in the control of
proliferation of different cell types, such as endothelial cells
or hematopoietic progenitors (10, 14–16). Because of their
heparin-binding motifs, CXCL4 and CXCL10 have been
shown to interfere with the binding of FGF-2 or VEGF165
to their receptors by impairing the growth factor’s ability to
form homodimers, competing with heparan sulfate pro-
teoglycans on the cell surface, or by directly binding to
these growth factors (36–37). Yet, a large body of evidence
indicates that another, still unidentified, receptor-mediated
mechanism exists. CXCL4 can antagonize EGF-mediated
endothelial cell proliferation by inducing an impairment of
p21CIP1/WAF1 down-regulation and this effect occurred
in a model system in which the stimulation is glycosami-
noglycan independent (38). Furthermore, the interference
by CXCL10 and CXCL4 with EGF-mediated calpain acti-
vation led to down-modulation of EGF-mediated migra-
tion of fibroblasts without affecting early postreceptor
events, but up-regulating cAMP levels (39). More im-
portantly, the endothelial cell stimulatory activity of
VEGF121, an endothelial cell mitogen that lacks both hep-
arin affinity and the property to bind CXCL4, was suscep-
tible to CXCL4 inhibition (29). CXCL4 can act even on
cells lacking heparan sulphates on their surface membranes
(37), and CXCL4 peptides made unable to bind heparan
sulphates still inhibited endothelial (40) and hematopoietic
cell growth (41), whereas CXCL4 peptides showing hepa-
rin-binding properties did not consistently exhibit inhibi-
tory activity (42). Finally, at concentrations inhibiting cell
proliferation, CXCL4 significantly reduced FGF2-induced
ERK activation, whereas the PI3K pathway was not af-
fected, thus excluding a simply competitive mechanism
(37). Taken together, these findings suggest that CXCL4
delivers its specific inhibitory signals through a not yet
identified receptor. It has also been reported that like
CXCR3 (11), the putative CXCL4 receptor is expressed
by microvascular endothelial cells only when they prolifer-
ate (43). The results of this study provide evidence that
CXCR3-B may represent the not yet identified functional
receptor for CXCL4. By contrast, CXCR3-B did not react
with any of the other 17 chemokines tested, including
CCL21, which reacts with both CCR7 and CXCR3 in
the mouse (44), as also shown by its activity on microglial
cells in CCR7 knockouts (45). However, differently from
its murine equivalent, human CCL21 was found to be un-
able to bind CXCR3 and exert any angiostatic activity (13,
27). Our results are consistent with these findings and sup-
port the concept that CCL21 binding to CXCR3 is a
mouse-restricted phenomenon. Thus, at least in humans,
CXCR3-B seems to act as the functional receptor for
the  four angiostatic chemokines, CXCL9, CXCL10,
CXCL11, and CXCL4.
The opposite biological activities mediated by CXCR3-A
and CXCR3-B suggest that the two receptors may triggerT
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different signal transduction pathways. Chemokine re-
ceptors are G protein–coupled receptors (GPCRs) that me-
diate chemotactic activity and Ca   flux induction through
the activation of PTX-sensitive Gi proteins (1, 2). Accord-
ingly, increased proliferative activity in CXCR3-A trans-
fectants could be reduced by PTX treatment. However,
PTX had no effect on the proliferation and survival of
CXCR3-B transfectants. Furthermore, only CXCR3-A
transfectants exhibited calcium influx in response to
CXCR3 ligands. This finding is consistent with the results
of previous reports showing that both activated lympho-
cytes and HMC respond with calcium influx to CXCL9,
CXCL10, and CXCL11 (1, 2, 19, 22), whereas endothelial
cells do not (12). Multifunctional coupling is common to
many GPCRs and has been previously described for the
putative CXCL10 receptor (46). Together, the lack of cal-
cium influx in response to ligands and PTX insensitivity
suggests the coupling of CXCR3-B to other types of G
proteins. This hypothesis was further supported by the se-
lective activation of adenylyl cyclase and consequent in-
crease of intracellular cAMP levels in response to CXCL10,
CXCL9, CXCL11, and CXCL4 in CXCR3-B, but not in
CXCR3-A, transfectants, a property usually related to
linkage of GPCR to Gs proteins (47). Of note, the increase
of cAMP levels in response to CXCL10 and CXCL4 inter-
action with an unidentified receptor had previously been
found to be associated with the inhibition of cellular prolif-
eration and chemotaxis in hematopoietic progenitors and
fibroblasts (16, 39). More recent data configure the adenyl-
ate cyclase pathway as an important pharmacological target
for the inhibition of angiogenesis, because cAMP up-regu-
lation in endothelial cells suppresses their migration and
proliferation through the enhancement of apoptosis (48).
Accordingly, CXCL10 increases intracellular cAMP levels
and inhibits the angiogenic activity of the GPCR-Kaposi’s
sarcoma-associated herpes virus, a property which is related
to a specific sequence of the NH2-terminal region of the
viral receptor (49, 50). CXCR3-A and CXCR3-B differ
for 52 amino acids at the NH2 end, leading to a change of
extracellular conformation that can account for the cou-
pling of CXCR3-B to different type(s) of G proteins (47).
Indeed, the active conformation of GPCR likely consists of
multiple subspecies that may favor different signaling path-
ways or regulatory events (47). Finally, CXCR3-B, but not
CXCR3-A, transfectants responded to CXCL10 and
CXCL4 with increased transcription of the cell cycle in-
hibitor p21CIP1/WAF-1. This is of importance because a
p53-independent up-regulation of p21 levels is responsible
for the antiangiogenic property of CXCL4 (38) as well as
the growth inhibitory effects of IFNs on different cell types
(51). Interestingly, the induction of p21 transcription is one
of the mechanisms involved in the antiproliferative effect
induced by Gs-mediated intracellular cAMP increase (52).
The results of this study also provide evidence for the in
vivo expression of CXCR3-B and thus for its possible phys-
iological relevance in angiogenesis. Indeed, two mAbs se-
lectively recognizing CXCR3-B were able to react with
endothelial cells from neoplastic tissues, but not with those
from their normal tissue counterparts. In conclusion, our
findings not only describe a novel chemokine receptor, but
also demonstrate that it is the previously unidentified func-
tional receptor of CXCL4 and a common mediator of the
effects of the four angiostatic CXC chemokines. Further
characterization of the CXCR3 gene regulation may refine
the ability to inhibit or promote blood vessel growth and al-
low the development of new effective therapeutic strategies.
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